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Autonomic innervation is an essential component of cardiovascu-
lar regulation that is first established from the neural crest (NC)
lineage in utero and continues developing postnatally. Although
in vitro studies have indicated that SH2-containing protein tyro-
sine phosphatase 2 (SHP-2) is a signaling factor critical for regulat-
ing sympathetic neuron differentiation, this has yet to be shown in
the complex in vivo environment of cardiac autonomic innerva-
tion. Targeting SHP-2 within postmigratory NC lineages resulted
in a fully penetrant mouse model of diminished sympathetic cardiac
innervation and concomitant bradycardia. Immunohistochemistry of
the sympathetic nerve marker tyrosine hydroxylase revealed a pro-
gressive loss of adrenergic ganglionic neurons and reduction of car-
diac sympathetic axon density in Shp2 cKOs. Molecularly, Shp2 cKOs
exhibit lineage-specific suppression of activated phospo-ERK1/2 sig-
naling but not of other downstream targets of SHP-2 such as pAKT.
Genetic restoration of the phosphorylated-extracellular signal-
regulated kinase (pERK) deficiency via lineage-specific expression
of constitutively active MEK1 was sufficient to rescue the sympa-
thetic innervation deficit and its physiological consequences. These
data indicate that SHP-2 signaling specifically through pERK in
postmigratory NC lineages is essential for development and main-
tenance of sympathetic cardiac innervation postnatally.
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Although autonomic innervation of the heart begins in utero,functional neurocardiac coupling continues postnatally. Auto-
nomic imbalance and irregular cardiac innervation density result
in deadly consequences such as cardiac arrhythmias, heart failure,
and sudden cardiac death (1–4). Although a balance between the
sympathetic and parasympathetic arms of the autonomic nervous
system is required to regulate heart rate, conduction velocity, and
the force of each contraction, sympathetic tone predominates in
determining the basal heart rate in the mouse.
The sympathetic nervous system arises from the neural crest
(NC) lineage. Trunk NC cells delaminate and migrate ventrally
through the somites to establish the sympathetic trunk ganglia near
the dorsal aorta (5, 6). Postmigration, cross-regulatory transcrip-
tion factors such as Mash1, Phox2a and 2b, and Gata3 (7–13) are
temporarily expressed and drive these NC cells to acquire a neu-
ronal fate and eventually to differentiate into sympathetic neurons
expressing both neuron specific β-tubulin (NSβT) and tyrosine hy-
droxylase (TH; the rate-limiting enzyme in catecholamine synthesis)
(14–19). From there, a subset of sympathetic NC cells undergoes a
second migration to the cervicothoracic and intrinsic cardiac
ganglia to establish populations of sympathetic neurons which
contribute to the cardiac plexus or “heart brain” (5, 20, 21). Recent
studies exploring the extensive complexity of autonomic cardiac
innervation revealed multiple levels of regulation and interaction
between parasympathetic and sympathetic arms of autonomic in-
nervation that converges in the heart brain to control cardiac
function (20–26). Sympathetic (i.e., TH-positive) innervation is
first observed at the base of the fetal heart; this innervation then
extends onto the surface of the atria and eventually to the ventricles
before following blood vessels into the ventricular wall to innervate
the myocardium and project to the sinoatrial and atrioventricular
nodes postnatally (27). The sympathetic innervation of the heart
is not functionally relevant (i.e., does not control heart rate) until
the second postnatal week of life in rodents (23, 28, 29), and the
adult pattern of innervation is not fully achieved until 3 wk after
birth (23, 30). This developmental process requires nerve growth
factor (NGF), which is produced by the target organ (the myo-
cardium in the case of the heart) and is the main neurotrophic
factor in establishing and maintaining sympathetic innervation
(31). In vitro studies have shown that NGF stimulates the dif-
ferentiation/neurite outgrowth of sympathetic neurons through
the SHP-2 (Src homology protein-tyrosine phosphatase 2)/ERK
pathway while mediating the survival of those same neurons
through the PI3K/AKT pathway (32–34). Interruption of the
NGF signaling pathway at either the ligand (NGF) or receptor
(TrkA) level results in pups that are viable at birth without any
gross defects; however, the pups fail to gain weight, have smaller
ganglia and fewer dendrites, exhibit total loss of sympathetic
innervation by 10 d after birth, and die ∼4 wk (Ngf null) or ∼8 wk
after birth (TrkA null) (35–38). Other models of altered sym-
pathetic innervation including a p75 null (a low-affinity receptor
of NGF) as well as systemic loss of Sema3a (a neural chemo-
repellent for sensory and sympathetic axons) and NC-restricted
deletion of the SEMA3A receptor Nrp1 all result in diminished
sympathetic innervation and subsequent bradycardia (24, 39, 40).
SHP-2 is a ubiquitously expressed nonreceptor tyrosine phos-
phatase involved in a variety of cellular functions including
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survival, proliferation, and differentiation (41–45). Significantly,
mutations in SHP-2 (encoded by PTPN11) result in LEOPARD
syndrome (LS; OMIM 151100), which is part of a family of
autosomal dominant syndromes termed “RASopathies” (46).
There are seven SHP-2 mutations associated with LS, all of
which are concentrated in the catalytic core of the protein. These
mutations have been shown in vitro to cause a decrease in cat-
alytic activity of SHP-2 and diminished MAPK signaling (42, 47,
48); however, there is still debate as to the mechanism for how
SHP-2 facilitates Ras/MAPK activation. It has been hypothesized
that SHP-2 dephosphorylates binding sites on Ras GAP receptors,
inactivates Grb2/Sos inhibitors, and activates Src family kinases
resulting in sustained Ras and subsequent ERK activation (42, 49,
50). LS itself is characterized by a constellation of symptoms such
as heart defects and electrocardiographic (ECG) abnormalities
including sinus bradycardia, although the ECG anomalies ob-
served are often complicated by structural defects (51, 52).
Due to its pivotal developmental role, systemic Shp2 deletion
results in early embryonic lethality (53, 54); however, several
conditional knockout (cKO) mouse models have investigated the
embryonic in vivo requirement of SHP-2 using various Cre
recombinase drivers. These models, although primarily embry-
onically lethal, have demonstrated that SHP-2 can play a role in
NC-mediated events such as cardiac outflow track development,
semilunar valvulogenesis (55), and Schwann cell-mediated mye-
lination of the peripheral nervous system (41, 56). Additional in
vitro studies have shown that SHP-2 is a key downstream factor
in NGF signaling during sympathetic neuronal differentiation and
subsequent neurite outgrowth (57–59), but the in vivo postnatal
requirement of SHP-2 within postmigratory NC lineage has re-
mained unclear.
In the present study, we sought to explore the in vivo postnatal
role of SHP-2 and its downstream effectors within the de-
velopment and maintenance of cardiac sympathetic innervation
and neurocardiac coupling. We targeted SHP-2 using a Postn-Cre
transgenic line that expresses Cre within postmigratory NC lin-
eages (60). The mutants exhibit failed sympathetic cardiac inner-
vation and concomitant bradycardia. Molecular analysis indicated
suppression of phosphorylated-extracellular signal-regulated ki-
nase (pERK) signaling within the sympathetic lineage. Further
investigation revealed that genetic restoration of ERK signaling
via lineage-specific expression of constitutively active mitogen-
activated protein kinase kinase-1 (caMEK1) was sufficient to
rescue the sympathetic innervation deficit and its physiological
consequences. These results demonstrate that SHP-2 promotion
of the ERK pathway is required in vivo for establishment of func-
tional sympathetic innervation within the postnatal heart. More-
over, these data provide a mechanistic basis for understanding
the lineage-specific aspects of clinical presentations that can occur
in diseases such as LEOPARD syndrome as well as other ECG
abnormalities resulting from disturbed pERK-dependent sympa-
thetic innervation.
Results
Shp2 cKOs Are Indistinguishable from Control Littermates at Birth.
Conditional Shp2 floxed mice containing a floxed exon 4 (50)
were intercrossed with Postn-Cre transgenic mice to generate
embryos that were deficient for SHP-2 protein within many
postmigratory NC lineages. Postn-Cre mice express Cre under
the control of a partial 3.9 kb Periostin promoter [as demon-
strated by R26r indicator mice (61)] within the E11.5 and older
peripheral nervous system (including autonomic, sensory, and
enteric components), as well as the endocardial cushion lineages
and future valves from embryonic (E) day 10 onward, but is
absent from the CNS (60, 62) (Fig. 1 A–E). Postn-Cre is also
expressed in fetal and neonatal cardiac fibroblasts (63) but is
absent from in utero and postnatal cardiomyocytes (63, 64).
Homozygous Shp2 cKO newborns were genotyped via PCR at
expected Mendelian inheritance ratios (n = 11 litters) and line-
age mapping using the R26r reporter (61) confirmed Cre-medi-
ated recombination in a pattern suggestive of postmigratory NC
lineages from E11.5 onward (Fig. 1 A–E). This demonstrated
that our conditional gene-targeting strategy did disrupt normal
SHP-2 expression in utero but did not cause any gross embryonic
defects and circumvented the in utero lethality observed within
other NC-restricted models of SHP-2 ablation (43, 53). Shp2
cKOs were indistinguishable from littermate controls at birth
(Fig. 1F), but by the second week of life, 100% of the mutants
exhibited diminished growth (n = 74/74 cKOs), and none sur-
vived past postnatal (P) day 21. Because a previously reported
Shp2 cKO model using Nestin-Cre exhibited a more severe
phenotype in males (65), we used PCR analysis [using Zfy sex
determination primers (66)] to determine sex of all neonatal
mutants; however, we did not detect any sex-related bias in our
model (n = 24 cKOs). Necropsy verified normal craniofacial and
cardiovascular development. Similarly, histology and R26r re-
porter analysis revealed that despite Cre expression within the
embryonic outflow tract and valves, both outflow tract morpho-
genesis and valvular maturation were unaffected; however, di-
minished peripheral and enteric innervation were noted and are
most likely contributing factors to the eventual lethality observed
(SI Appendix, Fig. S1). Lineage-specific recombination was ver-
ified in DNA isolated from mutant sympathetic trunk ganglia
(Cre-expressing) but not brain (Cre-negative as indicated by lacZ
expression for all ages of interest in this study) (Fig. 1G). De-
letion of exon 4 of Shp2 resulted in decreased SHP-2 protein
levels in microdissected partial heart/cardiac ganglia samples
(Fig. 1H) and NC-containing adrenals (SI Appendix, Fig. S2).
These tissues were chosen because they are enriched for Postn-
Cre–expressing cells (Fig. 1 A–E); however, it is important to
remember that neither the partial heart/cardiac ganglia nor the
adrenal gland is entirely Cre-positive so it is unlikely that ubiq-
uitous SHP-2 would be completely eliminated in these samples.
Postnatally, Shp2 cKOs Exhibit Diminished Neurite Outgrowth from
Cardiac Sympathetic Ganglia.To investigate the NC-specific effects
of Shp2 KO in postmigratory NC lineages, we carried out R26r
lineage mapping using the lacZ reporter system (61). The largest
component of sympathetic innervation projects to the dorsal sur-
face of the heart, and there, we observed significantly diminished
neurite outgrowth from cKO TH-positive cardiac ganglia at both
P2 and P14 (Fig. 1 I–T). Whole-mount lacZ spatiotemporal analysis
revealed that mutant cardiac sympathetic ganglia have fewer pro-
jections and that the neurites that are present are less robust (Fig.
1 I, J, O, and P) than those observed in age-matched littermate
controls (Fig. 1 L, M, R, and S). The cKO ganglia themselves,
however, do not appear grossly atrophic or morphologically
compromised. Detailed histology revealed typical neuronal archi-
tecture, namely, large dense nucleus with wavy axonal projections
emanating from both the control (Fig. 1 N and T) and the cKO
ganglia (Fig. 1 K and Q).
Decreased Sympathetic Innervation Is Observed in cKO Hearts. In
light of the decreased neurite outgrowth despite the normal gross
anatomical appearance of the ganglia, molecular characteriza-
tion of cKO cardiac ganglia using immunohistochemistry tech-
niques was conducted. Despite the in utero loss of SHP-2, E14.5
cKO ganglia consistently express neuron-specific NSβT, TrkA
(the high-affinity receptor of NGF, required for sympathetic
neuron survival), and the sympathetic neuronal marker TH (Fig.
2 A–C). A similar pattern was observed in E16.5 cKO ganglia (SI
Appendix, Fig. S3). However, postnatally, the expression of TH in
mutant ganglia is diminished at all ages investigated [P7 (Fig. 2F)
and P0, P6, and P18 (SI Appendix, Fig. S3)], whereas NSβT and
TrkA remain unaltered (Fig. 2 D and E). Moreover, the postnatal




















cKO ganglia are similar in size and cellularity to controls, and
TUNEL staining did not detect any apoptotic cells (Fig. 2G).
Radioactive in situ revealed mutant ganglia aberrantly express
markers of early embryonic sympathetic neuronal differentiation
because both Phox2a and Phox2b mRNA were expressed in mu-
tant but not control ganglia (Fig. 2 I–N). Additional embryonically
expressed sympathetic neuronal differentiation factors (Gata3,
Sox10, and Mash1) were also investigated but were found to be
negative in both controls and mutants. Significantly, global cardiac
sympathetic innervation of the cKO was compromised. At day 0,
nodules of TH-positive innervation can be observed in control
(arrows in Fig. 2O) but not mutant hearts (Fig. 2P), and by P7 the
mutant has substantially decreased TH-positive innervation (Fig. 2
Q and R), particularly around the blood vessels supplying the
ventricles (where sympathetic innervation is most pronounced in
the control). Diminished TH-positive innervation was also ob-
served in E16.5, P6, and P18 cKO hearts (SI Appendix, Fig. S3).
Despite diminished global cardiac sympathetic innervation, the
epicardial-to-endocardial gradient was present in controls and
mutants (SI Appendix, Fig. S3 I–L).To further validate diminished
TH expression in cKOs, Western analysis performed on isolated
hearts confirmed that TH levels were decreased by 70% in mu-
tants versus controls (Fig. 2H).
Shp2 cKOs Experience Sinus Bradycardia. To investigate whether the
observed SHP-2–dependent innervation defect has any func-
tional impact, longitudinal ECG analysis was carried out from P4
to P20. These studies revealed that cKOs exhibit sinus brady-
cardia (two-way ANOVA, P = 0.0012; Fig. 3 A and B) beginning
at P12, corresponding to the developmental timing of sympa-
thetic control of heart rate (28, 29). At P6, before the sympa-
thetic nervous system is thought to be functionally relevant for
establishing basal heart rate, there is no difference between
mutants and littermate controls (Fig. 3 A and B). However, by
P12 the heart rates of the control pups significantly increased
(this increase is associated with establishment of sympathetic
control of heart rate), whereas the cKO heart rate showed no
corresponding increase (Fig. 3 A and B). By P17 the heart rates
of the control littermates have plateaued, whereas the cKO heart
rates continue to decrease until lethality at 3 wk of age (Fig. 3 A
and B). No other arrhythmias or anomalies in the ECG wave
form (P-wave duration, PR, or QRS intervals) were observed
throughout the study with the exception of mild prolongation of
the PR interval immediately preceding death (SI Appendix, Table
S1). However, the first-degree heart block never progressed and
may be complicated by other issues such as the weight loss that
was observed in the final 24 h of life. QT intervals were also
examined, but the absence of a definitive T wave in many traces
negated the utility of such an investigation.
To examine the underlying cause of the sinus bradycardia,
several pharmacological interventions were used. Due to the
diminished sympathetic innervation observed in the cKO heart
(see Fig. 2), we hypothesized that the lack of adrenergic stimu-
lation was directly responsible for the observed phenotype. To
test this, we directly activated the β-adrenergic receptors (the
receptors that would normally be stimulated by sympathetic neu-
ron release of norepinephrine) by administering an i.p. injection of
the β-adrenoreceptor agonist, isoproterenol. Isoproterenol in-
creased the heart rates of both the control and mutant by 30%
with respect to their basal heart rates (Fig. 3C). Moreover, the
relative increase is consistent with the results reported from iso-
proterenol challenge tests carried out in adult mice (67) and con-
firms that the cKO cardiomyocytes are capable of responding to
adrenergic stimulation. In contrast, inhibiting parasympathetic
Fig. 1. Shp2 cKOs exhibit diminished neurite outgrowth from cardiac sympathetic ganglia. (A–E) Lineage mapping of Postn-Cre expression via lacZ staining
of E11.5 embryo (A), E16 embryo (B and C), and P2 pup (D and E) demonstrated Cre expression pattern suggestive of postmigratory NC lineages including the
craniofacial region, dorsal root ganglia, sympathetic trunk (* in A, B, and E), enteric ganglia, and peripheral nerves including those innervating the heart (A–
D; arrows in C). (F) Litter of P2 pups (mutants indicated by *) demonstrating Shp2;Postn-Cre cKOs are indistinguishable from littermate controls. (G) PCR
analysis of recombination efficiency demonstrating the lineage-specific nature of SHP-2 KO. Recombination efficiency was calculated via densitometry to be
78.8% within cKO ganglia (*). (H) Composite Western blot of heart and brain isolates confirming the lineage-specific nature of Shp2 cKO at the protein level.
SHP-2 levels were decreased in heart (*) but not brain isolates both in utero and postnatally. (I–K) P2 mutant TH-positive cardiac ganglia (arrows): whole-
mount lacZ staining (I), black and white reconstruction trace of surface neurite outgrowth (J), and histological section of lacZ stained ganglia counterstained
with eosin (K). (L–N) Same sequence of littermate P2 control. (O–T) Same sequence of P14 mutant (O–Q) and littermate P14 control (R–T). Note that both P2
and P14 cKOs exhibit reduced neurite outgrowth. [Scale bars: 100 μm (I, L, O, and R) and 20 μm (K, N, Q, and T).]
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activity with atropine had no significant effect on either mutants
or controls (SI Appendix, Fig. S4C). This was not particularly
surprising due to the fact that the parasympathetic influence on
murine heart rate is often minimal and subject to change on
differing genetic backgrounds (68, 69). To exclude the possibility
that the β-adrenergic receptors or their downstream signaling
effectors were misexpressed, we performed qPCR for both the
β1-adrenergic receptor (the primary adrenergic receptor expressed
in the heart) and adenylate cyclase-6 (the enzyme that produces
cAMP as a second messenger to propagate the adrenergic sig-
nal). Levels of both targets were found to be normally expressed
in P14 cKO hearts (SI Appendix, Fig. S4). Furthermore, heart Ngf
levels (as quantified via qPCR) were found to be the same be-
tween mutant and control for all ages investigated (Fig. 3D). This
was expected because regulation of NGF synthesis throughout
development is independent of sympathetic innervation or nor-
epinephrine secretion at the target organ (70), suggesting that
the diminished cardiac innervation does not affect the induction
of neurotrophic factors within the cKO heart.
To rule out any potential abnormalities in the sinoatrial node
(SAN) as possible contributing factors to the sinus bradycardia
observed, Hcn4 expression was examined. HCN4 is a key channel
located primarily in the SAN that helps maintain a regular heart
rhythm. Significantly, no disparities between control and mutant
SANs were observed (SI Appendix, Fig. S5 A–D). Also, because
Postn-Cre is expressed in cardiac fibroblasts which are responsible
for insulating the intrinsic conduction system of the heart, lacZ-
positive fibroblasts were quantified and found to be comparable
between mutants and controls at all ages investigated. Addi-
tionally, the levels of αSmooth muscle actin (a marker robustly
expressed by cardiac fibroblasts) were equitable, indicating that
cKO cardiac fibroblasts are present, are appropriately localized,
and express normal markers (SI Appendix, Fig. S5 E–H). Although
histology did not reveal any structural abnormalities, the micro-
structures of the control and mutant ventricular myocardium were
further investigated via electron microscopy. Similar to the histo-
logical, lineage mapping, and qPCR data above, the contractile
apparatus and mitochondrial architecture were not found to differ
between mutant and control (Fig. 3 E and F), indicating that
Postn-Cre–mediated lineage-restricted loss of SHP-2 does not
adversely affect the cKO heart itself.
Decreased pERK Is a Primary Signaling Abnormality Observed in
Mutants. SHP-2 is an important factor in several signaling cas-
cades, particularly modulation of the MAPK cascades (49). Pub-
lished data have shown that cKO of SHP-2 within premigratory NC
results in diminished pERK signaling and that transient ERK1/2
activation is necessary for expression of smooth muscle and neural
markers in NC in vitro (53). Similarly, SHP-2–deficent hemato-
poietic stem and progenitor cells show defective ERK and AKT
activation (71). In contrast, SHP-2–impaired cardiomyoctes ex-
hibit increased levels of phosphorylated AKT (pAKT) (72–74).
Because they are the two major postnatal effector molecules
studied in models of SHP-2 dysregulation, we examined pERK
and pAKT levels. Western analysis of microdissected heart/car-
diac ganglia protein isolates (containing only the top of the hearts/
atria that are enriched for Cre-positive cells) revealed that pERK
levels were decreased in cKOs by 50% at both E14.5 and P7 (Fig.
4). However, cKO pAKT levels were unaltered both in utero and
postnatally. These results indicate that the ERK1/2 branch of the
MAPK pathway as opposed to the AKT pathway is selectively
affected in the Shp2;Postn-Cre mutants and suggest that SHP-2
activity in the postmigratory NC is essential for pERK-mediated
differentiation and establishment of cardiac sympathetic neurons
but not their survival, which is dependent on AKT signaling.
Genetic Restoration of pERK Signaling Rescues the Cardiac Innervation
Defect.We next determined whether diminished pERK levels were
directly responsible for the sympathetic innervation phenotype ob-
served in Shp2 cKOs. To reactivate ERK1/2 signaling, a conditional
Fig. 2. Shp2 cKOs demonstrate diminished cardiac sympathetic innervation. (A–C) Immunohistochemistry (IHC) demonstrating equivalent NSβT (A), the NGF
receptor TrkA (B), and TH (C) expression in E14.5 littermate pairs of controls (Upper) and mutant (Lower) ganglia. (D–G) Adjacent sections of P7 ganglia
examined using IHC NSβT (D), TrkA (E), TH (F), and apoptosis (TUNEL; G). Note that P7 cKO ganglia exhibited diminished TH expression but are not apoptotic.
However, apoptotic cells are seen in adjacent tissue (arrow in cKO in G; n = 3 littermate pairs with two slides containing four to five sections of tissue each
analyzed). (H) Densitometry quantification of TH protein levels as detected by Western within isolated P14 hearts (n = 5). cKO TH levels were significantly
decreased (t test; P value = 0.0010). (I and J) In situ hybridization of mutant cardiac ganglia showing aberrant expression of Phox2a (an embryonic sympathetic
neuronal differentiation marker; I) in the context of diminished TH expression (arrow in J). (K and L) In situ hybridization of mutant cardiac ganglia showing
aberrant expression of Phox2b (an embryonic sympathetic neuronal differentiation marker; K). L shows phase contrast of the ganglia itself. (M and N)
Representative in situ hybridization of control cardiac ganglia showing no expression of Phox2b (M). N is phase contrast of the ganglia. (O and P) IHC de-
tection of TH-positive nerves on the left ventricle of a P0 control (O) and mutant (P). (Q and R) TH IHC of P7 ventricle of a control (Q) and mutant (R). Note the
lack of sympathetic innervation in the mutant heart at both ages but normal surface (arrows in O) and penetrating (Q) TH-positive nerves around blood vessel
(v) in wild types. Error bars represent SEM.




















floxed-stop model of caMEK1 (the effector directly upstream of
ERK) was crossed onto the Shp2;Postn-Cre background (Fig. 5A).
In this model, any cell expressing Cre will simultaneously delete
SHP-2 and express caMEK1 (75) in a lineage-restricted manner.
The Shp2;Postn-Cre;caMEK mice had significantly higher pERK
levels than their non-caMEK1–expressing mutant littermates, and
the Shp2;Postn-Cre;caMEK pERK levels were comparable to
wild-type age-matched littermate controls (Fig. 5B). Shp2;
Postn-Cre;caMEK TH levels were similarly restored to wild-type
levels (Fig. 5C). Moreover, immunohistochemistry revealed res-
toration of TH expression throughout the Shp2;Postn-Cre;
caMEK cardiac ganglia (Fig. 5 D–F) and an increase in TH-
positive innervation properly localized around the blood vessels in
the myocardium of the caMEK1-expressing cKO ventricle (Fig. 5
G–I). The restored sympathetic innervation on the dorsal surface
of the P14 Shp2;Postn-Cre;caMEK heart was verified via whole-
mount TH-immunostaining. This revealed substantially increased
arborization in the “rescued” mutant compared with the non-
rescued Shp2;Postn-Cre mutant (Fig. 5 J–L). Consequently, heart
rates of Shp2;Postn-Cre;caMEK rescued mutants were found to be
normalized to control levels at all ages investigated (P14 shown;
Fig. 5M). Thus, the rescue of sympathetic innervation functionally
Fig. 3. SHP-2 mutants exhibit progressive sinus bradycardia that is reversible by administration of a β-adrenergic agonist. (A) Characteristic ECG traces from
a wild-type littermate control (Upper) and a Shp2 cKO mutant (Lower) at three different ages [P6, before sympathetic innervation is functionally relevant to
heart rate; P12, once sympathetic innervation is functionally established; and P17, demonstrating the continual decline of mutant heart rate (indicated via *)]
are shown. (B) Graphic representation of average heart rates collected at the three ages in A. The heart rate of control animals increased from P6 to P12 and
then plateaued, whereas the cKO heart rate never significantly changed [two-way ANOVA, Sidak’s multiple comparisons +/+: P6 vs. P12, P < 0.05; P6 vs. P17,
p < 0.05; P12 vs. 17 = nonsignificant (P > 0.05); mutant: none of the comparisons of different time points were significant; control vs. mutant: P6, non-
significant; P12, P < 0.05; P17, P < 0.05 (n = 7–19)]. (C) Graphic representation of heart rate increase (normalized to basal heart rate, indicated by dotted line)
following i.p. injection of isoproterenol (2 mg/kg body weight). Both mutant and control heart rates increased with isoproterenol administration (paired t
test; P = 0.003); however, the genotype of the animal did not affect the degree to which the heart rate was elevated [two-way ANOVA interaction (genotype
x treatment): P = 0.905 (n = 4–6)]. (D) qPCR analysis illustrating comparable levels of Ngf between control and mutant hearts throughout the first 2 wk of life.
(E and F) Electron microscopy examination of control and mutant myocardium revealed normal contractile apparatus and mitochondrial (m) architecture in
the P14 mutant and control hearts. (Scale bar: 500 nm.) Error bars represent SEM.
Fig. 4. Shp2 cKOs exhibit decrease in cardiac pERK signaling both embryonically and postnatally, whereas pAKT signaling remains unaltered. (A) Repre-
sentative composite Western illustrating decreased pERK levels in mutant microdissected heart/cardiac ganglia (*) compared with wild type at both E14.5 and
P7 but equivalent total ERK levels (n = 5). However, cKO pAKT levels were unaltered at these ages (n = 3). (B) Densitometry quantification of pERK to tERK
ratios at E14.5 and P7 [t test, *P value < 0.05 (E14.5, P value = 0.0052; P7, P value = 0.0008)]. (C) Densitometry quantification of pAKT to tAKT ratios [t test,
P value = 0.498 (E14.5); P value = 0.758 (P7)]. Error bars represent SEM. The significant reduction in pERK levels suggests that a disproportionate amount of
the active pERK signaling in our neonatal microdissected heart/cardiac ganglia samples was within the NC/Postn-Cre-positive lineage. Moreover, unlike both
total ERK1,2 and SHP-2, which are ubiquitously expressed, pERK levels are known to fluctuate within a dynamic spatiotemporal tissue-restricted pattern in
both mouse (88) and human tissues (89).
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elevated the heart rates of the rescued mutants to those of litter-
mate controls. One aspect of the genetic intercross was that mixing
the SHP-2 cKOmodel (on a predominantly C57BL/6 background)
with the caMEK1 model (on a pure FVB/N background) equiva-
lently shifted the basal heart rates of both control and mutant
littermates ([C57BL/6 control, 499.77 ± 10.25 beats per minute
(bpm); mixed background control, 439.00 ± 14.00 bpm; C57BL/6
Shp2 cKO, 383.51 ± 5.26 bpm; mixed background Shp2 cKO,
342.83 ± 25.00 bpm; n = 6–20]. This is not surprising, because
different backgrounds can have widely divergent basal heart rates
(76). Because this shift affected all genotypes to the same ex-
tent and the relationship between control and Shp2 cKO heart
rates was not altered, it was not investigated further and was
instead considered evidence that the mechanism for cardiac
sympathetic innervation described in this study holds true
on more than one genetic background. Based on the neurite
Fig. 5. Lineage-specific expression of caMEK1 rescues the sympathetic innervation phenotype of Shp2 cKOs. (A) Schematic of caMEK1 genetic construct. (B)
Western analysis of heart isolates demonstrated that pERK levels in a rescued mutant (cKO + caMEK1) are similar to those in wild-type littermates, whereas
pERK in a cKO mutant is still drastically decreased. (C) Western analysis of heart isolates demonstrated that TH levels are also normalized in a rescued mutant
and are similar to a wild-type littermate, but TH levels relative to α-tubulin loading control are still drastically decreased in cKO hearts. (D–F) TH IHC of P14
control (D), rescue (E), and mutant (arrow in F) cardiac ganglia demonstrating a restoration of TH expression in the rescued mutant ganglia. (G–I) TH IHC of
P14 control (G), rescue (H), and mutant (I) left ventricle demonstrating increased TH-positive innervation in the rescued mutant ventricle (arrows in H). (Scale
bar: 20 μm.) (J–L) Whole mount TH IHC showing the dorsal surface pattern of sympathetic innervation in a P14 control (J), rescued mutant (K), and mutant (L)
heart. (M) ECG analysis of average heart rates of control, rescue, and mutant littermates at P14 [one-way ANOVA P = 0.0113; Tukey’s multiple comparisons
test: +/+ vs. rescue = nonsignificant, +/+ vs. cKO = significant (P < 0.05), rescue vs. cKO = significant (P < 0.05) n = 5–20]. Note that lineage-specific expression of
caMEK1 restores the mutant heart rates. (N) Proposed model for underlying signaling cascade responsible for the sympathetic innervation defects within
Shp2 cKOs. Error bars represent SEM.




















outgrowth studies, innervation phenotypes, pERK-dependent
rescue, and previous in vitro work, we propose a schematic
detailing the likely signaling mechanism as explanation for
these data (Fig. 5N).
Discussion
In this study we explored the role of SHP-2 and downstream
pERK signaling in the context of sympathetic neuron differen-
tiation and innervation maintenance of the developing heart.
Although much is known about the molecular mechanisms reg-
ulating sympathetic neuron growth and differentiation in vitro,
many of these pathways had yet to be investigated in vivo. We
generated a lineage specific KO of Shp2, which exhibits postnatal
failure of sympathetic cardiac innervation. Furthermore, the fact
that restoration of pERK levels rescued this phenotype indicates
that pERK signaling is necessary for peripheral sympathetic in-
nervation in vivo. SHP-2 has been shown in vitro to be a required
intermediary linking NGF signaling to pERK elevation, which is
essential for sympathetic neuron differentiation (57–59, 77–81).
When the NGF–SHP-2–ERK pathway is interrupted in model
systems such as PC12 cells and explanted superior cervical gan-
glia via pharmacological or genetic means, sympathetic neurons
fail to differentiate (as indicated by the paucity of neurites pro-
jected from the cell body) (57–59, 77–81). Although some in vivo
models have indicated an important role for MAPK signaling in
sensory innervation patterning (41), other groups have attemp-
ted to investigate the effect of SHP-2 mutations on sympathetic
innervation in vivo but were unable to recapitulate the in vitro
results (77); our Shp2 cKO successfully demonstrates that SHP-2
and subsequent pERK elevation are required for sympathetic
innervation of the developing heart. Although the Postn-Cre is
expressed from E10.5 onward, phenotypic differences between
cKOs and controls were not observed until after birth. This could
be due to the fact that NGF and its downstream signaling are not
required for sympathetic innervation until E16.5 (82), but in the
absence of an inducible Cre we cannot exclude the possibility
that NC progenitors are altered or misspecified early in de-
velopment and the effects are not manifested until after birth.
This is a limitation of the current study and is an avenue of future
research when the appropriate genetic tools become available.
Although global cardiac sympathetic innervation was dimin-
ished in cKOs, the TH-positive intrinsic cardiac ganglia exhibited
decreased neurite outgrowth and TH expression. This emphasizes
that these structures are subject to the influences of SHP-2 and
pERK signaling and, in the context of sinus bradycardia, rein-
forces their functional role in the heart brain and the idea that they
are involved in heart rate regulation particularly in the first 2–3 wk
of life (22, 23, 25, 26). The dearth of axonal projections emanating
from these ganglia combined with the loss of sympathetic-specific
TH expression despite continued expression of the generic neuronal
marker NSβT suggests that failure of sympathetic neurons to
differentiate or to maintain their differentiated state may be the
underlying mechanism for the altered sympathetic innervation in
mutant hearts. Aberrant expression of embryonic sympathetic
neuron differentiation transcription factors such as Phox2a and
2b which regulate TH and Dopamine β-hydroxylase expression
(11) further supports this hypothesis. Additionally, the absence
of apoptotic cells in mutant sympathetic ganglia emphasizes the
fact that MAPK signaling is essential for differentiation but not
for the survival of sympathetic neurons. Thus, although these SHP-
2–regulated protein kinases have pleotropic effects on the cell, they
likely elicit some of their effects by the phosphorylation of down-
stream mediators of sympathetic nervous system homeostatic gene
expression.
MEK1 is an ideal target for a genetic rescue of our model
because the only known substrates of MEKs are ERK1/2, and
reciprocally, the only known activators of ERK1/2 are MEK1/2
(58). Although both MEK1 and 2 are known to activate ERK,
MEK1 has been more extensively studied and is considered the
more physiologically relevant isoform particularly downstream of
RAS because MEK1 but not MEK2 has been found to associate
with RAS in a signaling complex (83). Specifically, in PC12 cells
an inactivating mutation in MEK1 blocks sympathetic differen-
tiation, whereas activating mutations facilitate neurite outgrowth
even in the presence of dominant-negative SHP-2 or in the ab-
sence of NGF (57, 59). Introduction of caMEK driven by the
same conditional system as our Shp2 cKO allowed us to simul-
taneously delete SHP-2 and express caMEK in postmigratory
NC. Significantly, this model resulted in a physiological increase
in pERK levels (restored to control levels) because unchecked
elevation of pERK can result in cardiac valvular and septal ab-
normalities (84). The spatiotemporal precision of this genetic
model has allowed us to begin to parse out the ERK-dependent
from the ERK-independent effects of Shp2 cKO. The rescued
mutants (Shp2;Postn-Cre;caMEK) still exhibit failure to thrive
and eventually die, although a significant portion (∼50%) survive
past weaning, whereas all nonrescued mutants die before P21.
The delay but not complete rescue of lethality indicates that
there may be both ERK-dependent and ERK-independent
mechanisms contributing to the eventual death of the mice. For
example, the peripheral innervation defects and altered enteric
innervation, although not the focus of this study, could be con-
tributing factors to lethality in both the cKO and rescued model
(SI Appendix). An alternative explanation is that there is not
complete rescue due to the fact that dynamic pERK regulation
cannot be achieved through constitutive expression of caMEK1.
Significantly, our findings indicate that establishment of sympa-
thetic innervation of the heart is an ERK-dependent event be-
cause all aspects of the cardiac innervation phenotype observed
in the Shp2 cKO were rescued by lineage-restricted caMEK1.
This model provides a useful tool in which to identify lineage-
specific proximate targets of SHP-2 during autonomic innervation
and establishment of a mature functioning cardiovascular system.
Functionally, we have demonstrated that SHP-2–dependent
sympathetic deficiency leads to sinus bradycardia. Because there
is diminished sympathetic innervation in the mutant heart and
the innervation which is present lacks TH and thus cannot pro-
duce catecholamines (i.e., norepinephrine) which would normally
act to maintain the heart rate, we hypothesized that delivering an
exogenous β-adrenergic agonist (isoproterenol) would stimulate
both the control and the mutant heart to beat faster. Because
isoproterenol did increase both the control and the mutant heart
rates equivalently, we were able to conclude that the mutant heart is
functionally capable of responding to catecholamines and main-
taining a rapid heart rate (excluding the possibility of conduction or
inherent structural defects as a cause of the bradycardia). Fur-
thermore, because administration of atropine did not elevate heart
rate, indicating that parasympathetic tone is not responsible for
the slowed heart rate, we concluded that the absence of sym-
pathetic tone is the direct cause of the sinus bradycardia ob-
served in Shp2 cKOs. This hypothesis was further verified by
rescuing the sympathetic innervation phenotype by conditionally
expressing caMEK1 which abolished the sinus bradycardia.
Through lending mechanistic insight to early sympathetic inner-
vation and heart rate regulation, this model also allows for in-
vestigation of how the loss of SHP-2 function in diseases such as
LEOPARD syndrome can lead to the ECG abnormalities charac-
teristic of the syndrome (47, 51). Although these abnormalities are
not very well characterized and are often complicated by struc-
tural cardiac defects and a uniform decrease of SHP-2 signaling
within all tissues at all ages (51, 85–87), our cKO mouse provides
an opportunity to study SHP-2’s spatiotemporal role in estab-
lishing aberrant ECG patterning in isolation from compounding
structural cardiac defects.
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Materials and Methods
Animal use was in accordance with institutional guidelines, and all
experiments were reviewed and approved by the Institutional Animal
Care and Use Committee at Indiana University-Purdue University Indi-
anapolis. Floxed Shp2 mice were generated as described previously (50)
and intercrossed with Postn-Cre [MGI:3775923] mice on a C57BL/6 back-
ground to generate lineage-restricted cKO offspring (60) containing a 3.9
kb partial Periostin promoter that drives Cre expression within the NC-
derived peripheral nervous system (including Schwann cells as well as
sensory, enteric, and sympathetic neurons) (62). To facilitate lineage map-
ping, floxed Shp2;Postn-Cre mice were intercrossed with β-galactosidase in-
dicator mice (61). To reconstitute pERK expression within the Shp2 cKO
lineage, the floxed Shp2;Postn-Cre mice were intercrossed with CAG-
caMEK1 mice (75) which were on a pure FVB/N background. The resulting
♂CAG-caMEK1;Postn-Cre;Shp2f/+mice were bred to existing ♀Shp2f/f;R26r/R26r
mice which yielded our desired compound mutant experimental genotype:
CAG-MEK1;Postn-Cre;Shp2f/f;R26r ∼3/16 pups born.
Additional methods are detailed in SI Appendix.
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